Studies have shown that the aberrant expression of MTFP1 in HER2-positive breast cancer is closely related to aggressiveness, which may affect the therapeutic sensitivity of cancer cells by regulating metabolic reprogramming (Baek et al., 2023). This evidence concerns the gene ERBB2 and breast cancer.